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F
or prescription drugs, 
demonstrated benefits define 
the parameters of acceptable 
risks. For example, liver toxicity may 
be acceptable in a drug approved for 
cancer, but unacceptable in a drug 
approved for acne. Government 
regulatory bodies review laboratory, 
animal, and human data to confirm 
that a drug has the claimed efficacy 
and safety prior to approving its release 
in the market for specific approved 
(“labeled”) uses.
Once a drug is approved for at least 
one indication, it may be prescribed 
off-label for a different condition, a 
different population, or in a different 
dose than what the drug is approved 
for. However, off-label uses have not 
been subject to the testing and review 
that is a precondition for marketing 
approval. The scientific review of 
evidence of effectiveness and safety that 
regulators weigh prior to approval for a 
labeled indication protects the patient. 
With off-label use, this protection often 
does not exist.
Off-label prescription of a drug is 
generally legal, but promotion of off-
label uses by a drug manufacturer is 
usually illegal. This paper addresses 
public health issues associated with 
off-label use, and describes techniques 
by which pharmaceutical companies 
covertly promote off-label use even 
where such promotion is illegal. 
Risks and Benefits for Patients
Off-label use is sometimes unavoidable; 
three-quarters of marketed prescription 
drugs have no labeling indications for 
children, a population only recently 
included in clinical trials [1]. Pregnant 
women are also routinely excluded 
from studies, so most drug treatment 
during pregnancy is off-label. 
Some off-label use is demonstrably 
beneficial. For example, in the United 
States, misoprostol, a prostaglandin, 
is approved only to prevent ulcers. 
However, misoprostol is widely used off-
label for ripening the cervix, inducing 
abortion, and other indications, and 
more than 200 studies involving more 
than 16,000 pregnant women support 
the use of misoprostol in obstetrics [2].
Pregnant women and children, 
however, do not account for most 
off-label use. In 2001, 150 million off-
label prescriptions were written—21% 
of all prescriptions written for 160 
common medications in the US. 
About three-quarters (73%) of off-
label prescriptions were written for 
conditions for which there was little or 
no scientific support for efficacy [3]. 
Up to 75% of drug use in cancer care, 
and about 90% of drug use in rare 
diseases, is off-label [1].
Off-label use of drugs has been 
associated with serious adverse effects. 
For example, Duract (bromfenac), 
an analgesic, was approved only for 
treating acute pain, and only for short-
term use (less than ten days). However, 
some physicians prescribed Duract 
off-label for longer durations. Duract 
caused liver failure, and was withdrawn 
from the market less than a year after 
approval [4]. The appetite suppressant 
Pondimin (fenfluramine), approved for 
short-term use, was widely prescribed 
with phentermine and used long-term. 
The off-label combination “fen-phen” 
caused valvular heart disease [4,5]. 
In children, off-label use of drugs is 
associated with an increased number 
and severity of adverse effects [6].
Risks—and Benefits—for Profits
From a business standpoint, increased 
off-label use means larger revenues 
from larger user populations, especially 
for products with narrow indications. 
For example, a company that knows 
that an approved leukemia drug 
reduces facial wrinkles could fund an 
efficacy trial in people with wrinkles 
in order to garner a new indication. 
However, clinical trials are expensive, 
and the results could decrease sales by 
showing that the drug is ineffective, 
or has significant safety problems. 
A company-funded long-term trial 
that tested the efficacy of Vioxx 
(rofecoxib) for colon polyps turned 
up cardiovascular risks that eventually 
resulted in the drug being withdrawn 
[7].
The disadvantage of an off-label 
market is limited growth, because 
a company cannot legally promote 
sales. Warner-Lambert, a subsidiary of 
Pfizer, paid US$430 million in criminal 
fines and civil payments for off-label 
promotion of Neurontin (gabapentin) 
[8].
Although off-label use is usually 
advantageous for companies, 
occasionally it works against company 
goals. For example, despite robust 
evidence for the safety and efficacy 
of misoprostol in obstetrics, the 
manufacturer, perhaps not wanting to 
be associated with an abortion drug, 
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would not seek approval from the US 
Food and Drug Administration (FDA) 
for any reproductive health uses [9]. 
Publicly funded studies were eventually 
performed [10].
Genentech found itself in the 
awkward position of battling off-label 
use of its own product. After Lucentis 
(ranibizumab) was approved to treat 
age-related wet macular degeneration, 
ophthalmologists quickly substituted 
Genentech’s Avastin (bevacizumab), 
a similar, cheaper drug approved for 
cancer treatment. While arguing that 
no trials supported bevacizumab for 
age-related wet macular degeneration, 
Genentech refused to conduct 
comparative trials, presumably because 
a finding of equivalency would 
undercut sales of the more expensive 
drug. The National Eye Institute of the 
National Institutes of Health plans a 
trial comparing the two drugs [11].
How To Promote Off-Label
One of us (DM) worked in the 
pharmaceutical industry as a physician 
in medical affairs, supporting 
marketing, for over five years, and 
both authors have current contacts 
within the industry. Any unreferenced 
material that follows is from our 
personal experience, contacts, or 
information available in public fora 
such as industry discussions and 
presentations at trade shows. 
In development, drugs may be 
promising for several uses, and 
companies must choose one or two 
conditions on which to focus research. 
Ease of approval is the most important 
factor in this decision. If extensive 
off-label use is anticipated, a company 
may seek approval for a narrow 
indication in order to speed a drug to 
market. In other words, a drug may be 
approved for a decoy indication while 
an extensive off-label campaign is not 
disclosed to regulators. For example, 
a company that plans to promote a 
drug off-label for cancer prevention 
could avoid the costs and delay that 
a long-term trial entails by instead 
funding a relatively inexpensive trial 
of ulcer treatment, or—even better for 
business—rabies. Rabies is rare, and in 
the US, treatments for rare diseases are 
“orphan drugs,” eligible for expedited 
six-month FDA reviews. Orphan drugs 
enter the market faster.
Once a drug is approved for a 
decoy indication, labeled and off-label 
promotion may occur concurrently. 
Journal advertising and direct mail 
channels are used to market labeled 
indications. Off-label campaigns are 
launched outside of the sales force. 
Nationally known, influential 
academic physicians help “word-of-
mouth” or “buzz” marketing. These 
“thought leaders” or “key opinion 
leaders” (KOLs) support labeled 
marketing efforts as well, but they are 
considered crucial for the promotion of 
off-label uses. Industry-paid KOLs are 
never company employees. Rendering 
purportedly independent opinions, via 
articles and lectures, KOLs are able to 
elude laws against off-label promotion.
Commentaries and Case Studies
In the pharmaceutical industry, there 
are two ways to market an approved 
drug for a new use: the “indication” 
route—performing studies necessary 
for regulatory approval—or the 
“publication” strategy, which stimulates 
off-label prescribing by using research 
“to disseminate the information as 
widely as possible through the world’s 
medical literature” [12]. 
Clinical studies provide key 
references for the industry-produced 
reviews and commentaries, signed by 
KOLs, used for promoting off-label 
sales. Case studies about off-label uses 
may be solicited; physicians may be 
paid for combing patient medical 
records for cases that help industry 
goals. A physician—or a medical 
writer—will write up the case or case 
series, which may be submitted for 
publication or presented as a meeting 
abstract. Industry-sponsored reprints 
may be included in continuing medical 
education (CME) activities sponsored 
by medical education companies 
(MECs), often distributed by direct 
mail.
Marketing via Meetings: Abstracts 
and Posters
Posters and abstracts presented 
at medical meetings create buzz, 
especially if a press release garners 
media attention. Meeting abstracts 
and posters are considered cutting-
edge, but the information is almost 
always incomplete and usually lacks 
peer review. While abstracts must be 
submitted six months before meetings, 
posters can be altered, without review, 
up to the day of the meeting. Poster 
reproductions are made available to 
meeting attendees, and are an ideal 
form of stealth marketing. 
Abstracts or posters may be 
“published” in conference proceedings, 
medical journals, “throwaway” journals, 
or industry-sponsored medical journal 
supplements. These industry-generated, 
non-peer-reviewed, covert promotional 
pieces are now citable items that are 
provided to physicians by a company’s 
medical affairs office to support off-
label use, and can be referenced in 
peer-reviewed articles, ads, and other 
marketing materials. 
Industry-sponsored abstracts, posters, 
and publications are designed to 
serve marketing purposes and so must 
foster positive impressions of targeted 
drugs. If a poster or abstract generates 
positive buzz, study publication is 
unnecessary, and could even hurt sales. 
For example, a poster might present 
preliminary results of a study that 
showed promising effects of a drug in 
50 patients. Perhaps, after 200 patients 
finished the study, the drug proved no 
better than placebo. A company could 
then decide against publishing the trial. 
Doctors exposed to positive preliminary 
results and protected from negative 
final results would still regard the drug 
favorably.
Medical and Graduate Education
Publications and posters provide the 
foundation for the medical education 
programs that are key for promoting 
off-label uses [12,13]. “Medical 
education drives this market!” stated 
a Parke-Davis business plan revealed 
in a legal case regarding off-label 
promotion [12]. MECs know that 
accredited CME programs funded 
by unrestricted grants must favor 
marketing messages. The easiest way to 
accomplish this goal is to use company 
speakers trained for unaccredited (non-
CME) promotional presentations. 
Physician-speakers are trained 
in presenting unaccredited talks, 
sometimes called “dinner talks” or 
“lunch-and-learns.” This training, 
using company slides, often occurs at 
resorts. Some speakers are genuinely 
unaware of the marketing messages 
they are responsible for disseminating. 
For example, messages that a 
certain disease is underdiagnosed, 
undertreated, or more serious than 
commonly believed can bolster a 
company’s marketing goals even if 
drugs are never mentioned. PLoS Medicine  |  www.plosmedicine.org 1434 October 2008  |  Volume 5  |  Issue 10  |  e210
Physicians trained in unaccredited 
talks may present the same talk at 
a CME event. Most industry-paid 
physicians believe that they maintain 
intellectual independence. Presenting 
different statements in different 
settings would create cognitive 
dissonance. Psychologically, it is easier 
to believe that what one is saying is 
scientific and accurate, and thus to 
say the same thing at accredited and 
unaccredited programs. 
“Unrestricted” grants provided to 
departments at academic medical 
centers for grand rounds and lunch 
conferences depend on a sense of 
obligation rather than a quid pro 
quo. When lists of recommended 
speakers are supplied to organizers, it is 
unstated, but nonetheless understood, 
that company-paid speakers will be 
included in the lecture series. 
Although company-provided 
materials usually do not recommend 
off-label use, speakers may modify the 
slides, or simply address off-label uses 
verbally. Companies are supposed to 
stop using speakers who consistently 
promote off-label uses, but that may 
not happen. 
The Role of Reps 
In the US, although pharmaceutical 
representatives are not supposed 
to detail doctors on off-label uses, 
representatives are rated, and 
compensated, based on sales. As one 
industry consultant quoted in Medical 
Marketing and Media stated, “Let’s say 
the sales goal [for a drug] is larger than 
if every patient over 60 is already on 
it. Divide that down to territories, and 
everybody has to meet it. The message 
is, sell off-label.” A pharmaceutical 
industry attorney quoted in the same 
article stated, “Before engaging in off-
label promotion, companies should 
ascertain the risk profile, safety, 
efficacy, and potential commercial 
benefits of the use—without 
committing that last bit to print” [14]. 
In other words, illegal promotion may 
be cost-effective if potential profits 
trump potential fines.
Companies distance themselves from 
“rogue” reps caught promoting drugs 
off-label, but in practice, monitoring 
reps may be bad for the bottom 
line. Some marketing information 
companies track rep behavior, usually 
by interviewing physicians, and sell 
this information to pharmaceutical 
companies interested in the behavior 
of their own—or competing—reps. 
Some companies, however, ask that 
potential negative information about 
their own reps be removed before the 
information is supplied [15]. 
Skilled pharmaceutical 
representatives can solicit questions 
about off-label use from doctors. After 
“cueing” the doctor to ask an off-label 
question, the rep can fill out a postcard 
or call the company to send a packet 
of off-label information from the 
medical affairs office. The packet may 
contain company-approved reprints 
and a “standardized letter,” created 
by the drug information department 
of the company, discussing any 
research on the off-label use. The US is 
considering loosening restrictions on 
the distribution of reprints regarding 
off-label uses by pharmaceutical 
representatives. In February 2008, 
the FDA released a draft guidance for 
industry that would allow distribution 
of reprints from peer-reviewed 
publications with genuine editorial 
boards.
Coverage through Compendia
Compendia are compilations of drug 
information that include both on-
label and off-label uses. Medicare,
Medicaid, and many other insurers will 
cover off-label uses of reimbursable 
drugs included in major compendia, 
including the American Hospital 
Formulary Service–Drug Information 
(American Society of Health-System 
Pharmacists), the US Pharmacopoeia–
Drug Information (Micromedex, a 
division of the Thomson Publishing 
Company), and DRUGDEX. 
Pharmaceutical companies strive 
to establish good relationships with 
compendia staff, and may assign an 
employee as the designated compendia 
contact. The pharmacists who write 
compendia listings are very busy, 
and are usually delighted to receive 
organized packets of scientific articles, 
abstracts, and contact information. 
Using company-provided articles 
(which always contain marketing 
messages) saves time; all of the 
company’s assertions for off-label use 
may be transferred intact to the final 
product. Companies celebrate new 
compendia listings because expanded 
insurance coverage ensures more sales.
Drug information listings, similar 
to compendia, usually solicit company 
input and review. Although companies 
do not pay for listings, they may offer to 
buy hundreds or thousands of reprints 
for sales staff. In any case, it makes 
sense to contribute to entries that show 
company data in the best light.
Discussion/Conclusions
While off-label use is sometimes 
necessary, it should be undertaken 
with care and caution due to the 
uncontrolled experiment to which a 
patient is being subjected. Valuable 
off-label uses should be discussed by 
unbiased researchers in bona fide 
medical journals. Promising therapies 
should be tested in clinical trials. Truly 
useful off-label benefits of drugs will 
not remain a secret.
Pharmaceutical companies cannot be 
expected to police off-label promotion 
by sales representatives when such 
promotion financially benefits both the 
reps and companies. Washington D. C. 
recently became the first jurisdiction 
to require licensure of pharmaceutical 
sales representatives. The SafeRx Act 
requires drug reps to be held to a 
professional code of conduct, prohibits 
them from engaging in deceptive or 
misleading marketing, and requires 
continuing education as a requirement 
for license renewal [16]. If the city 
monitors and punishes infractions, this 
novel approach could mitigate off-label 
promotion.
States and other jurisdictions have 
a duty to protect the health of the 
public. Allowing off-label promotion of 
drugs for untested, unproven benefits 
maximizes industry profits at the 
expense of public health. A risk–benefit 
ratio cannot be assessed without 
knowing whether benefits exist. Where 
no benefits exist, no risk is acceptable. 
Pharmaceutical marketing has 
distorted the discourse on off-label uses 
and encouraged the unmonitored, 
potentially dangerous use of drugs 
by patients for whom risks and 
benefits are unknown. Companies 
that engage in off-label promotion 
should be heavily fined and their 
future marketing practices subject 
to increased scrutiny by regulatory 
agencies. Perhaps financial incentives 
could be provided to reward physicians 
and others who report off-label 
promotion. Such programs would 
target only industry representatives, not 
clinicians, and would be easily covered 
by industry fines. Restrictions on off-PLoS Medicine  |  www.plosmedicine.org 1435 October 2008  |  Volume 5  |  Issue 10  |  e210
label promotion of drugs should be 
strengthened, not gutted.  
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